Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

VaxGen Warning Letter Questions Anthrax Vaccine Promotions

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

CBER’s advertising branch cites VaxGen for promotions of its experimental anthrax vaccine, but the claims resemble those made in a 2004 HHS press release.

You may also be interested in...



The Pipeline Promotion Dilemma: FDA Cites Description Of Investigational Anthrax Vaccine

PharmAthene makes changes to fact sheet on SparVax after CBER's advertising branch finds that the claims "strongly suggest" the vaccine will be safe and effective.

The Pipeline Promotion Dilemma: FDA Cites Description Of Investigational Anthrax Vaccine

PharmAthene makes changes to fact sheet on SparVax after CBER's advertising branch finds that the claims "strongly suggest" the vaccine will be safe and effective.

VaxGen Anthrax Vaccine Delayed

VaxGen expects to supply its recombinant protective antigen anthrax vaccine to the U.S. government beginning in the fourth quarter of 2006, the firm announced Nov. 1

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS064100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By